Details of the Drug Combination

General Information of Drug Combination (ID: DCUDB90)

• Drug Combination Name: Raloxifene + Indazole derivative 5
• Indication: Invasive ductal carcinoma; Status: Investigative [1]
• Component Drugs:
  Raloxifene (DMDKF3M): Small molecular drug
  Indazole derivative 5 (DMM1I8R): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: BT-549
  Zero Interaction Potency (ZIP) Score: 7.84
  Bliss Independence Score: 6.58
  Loewe Additivity Score: 4.38
  LHighest Single Agent (HSA) Score: 3.15

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Raloxifene

Disease Entry	ICD 11	Status	REF
Osteoporosis	FB83.0	Approved	[2]

Raloxifene Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Modulator	[3]

Raloxifene Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[4]

Raloxifene Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[5]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Metabolism	[6]
UDP-glucuronosyltransferase 1A10 (UGT1A10)	DEL5N6Y	UD110_HUMAN	Metabolism	[7]

Indazole derivative 5 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
ABL T315I mutant (ABL T315I)	TTZJTWA	ABL1_HUMAN	Inhibitor	[8]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I)	TTIV39N	BCR_HUMAN-ABL1_HUMAN	Inhibitor	[8]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Clear cell renal cell carcinoma	DCUBDT0	786-0	Investigative	[9]
Clear cell renal cell carcinoma	DCVKR3P	A498	Investigative	[9]
Papillary renal cell carcinoma	DCN2L01	ACHN	Investigative	[9]
Carcinoma	DCH740C	MCF7	Investigative	[1]
Colon adenocarcinoma	DCAQVAP	COLO 205	Investigative	[1]
Invasive ductal carcinoma	DCQ746K	T-47D	Investigative	[1]
Invasive ductal carcinoma	DC6AENR	HS 578T	Investigative	[1]
Adenocarcinoma	DCAZJNZ	DU-145	Investigative	[10]
Adenocarcinoma	DC9LFMS	NCIH23	Investigative	[10]
Adenocarcinoma	DCSWG3U	HCT-15	Investigative	[10]
Amelanotic melanoma	DCC5S9O	M14	Investigative	[10]
Cutaneous melanoma	DCX3858	SK-MEL-5	Investigative	[10]
Cutaneous melanoma	DCECULE	SK-MEL-28	Investigative	[10]
High grade ovarian serous adenocarcinoma	DCVZH0V	OVCAR-8	Investigative	[10]
High grade ovarian serous adenocarcinoma	DCZJL9V	OVCAR-5	Investigative	[10]
Large cell lung carcinoma	DCCO7YX	NCI-H460	Investigative	[10]
Lung adenocarcinoma	DCL3LLH	HOP-62	Investigative	[10]
Malignant melanoma	DCCMPW8	UACC62	Investigative	[10]
Melanoma	DCO0NIJ	SK-MEL-2	Investigative	[10]
Melanoma	DCO3YTC	UACC-257	Investigative	[10]
Non-small cell lung carcinoma	DC850Z8	HOP-92	Investigative	[10]
Ovarian serous cystadenocarcinoma	DC7E0J9	SK-OV-3	Investigative	[10]
Prostate carcinoma	DCYNOA7	PC-3	Investigative	[10]

References

• [1] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
• [4] Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. Transl Res. 2012 Oct;160(4):298-308.
• [5] The role of P-glycoprotein in the bioactivation of raloxifene. Drug Metab Dispos. 2006 Dec;34(12):2073-8.
• [6] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [7] Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30.
• [8] Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
• [9] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [10] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.